Compare Stocks → A.I. is a Tidal Wave - Here’s What to Buy (From Chaikin Analytics) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADILNASDAQ:AKTXNASDAQ:BFRINASDAQ:GRTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$1.76+3.5%$1.75$0.77▼$14.00$6.89M1.47.92 million shs122,536 shsAKTXAkari Therapeutics$1.70+10.4%$1.72$1.08▼$5.50$12.20M0.9914,279 shs162,994 shsBFRIBiofrontera$1.96+6.5%$1.46$0.61▼$13.42$9.36M0.6589,739 shs70,318 shsGRTXGalera Therapeutics$0.19$0.20$0.09▼$3.59$10.13M2.021.87 million shs726,364 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals+3.53%+2.92%+43.09%+53.04%-78.00%AKTXAkari Therapeutics+10.39%+42.86%+12.58%-32.27%-53.42%BFRIBiofrontera+6.52%+18.07%+2.08%+45.19%-83.53%GRTXGalera Therapeutics+1.88%+3.89%+14.20%+5.74%-93.96%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial Pharmaceuticals0.1661 of 5 stars0.02.00.00.02.30.80.6AKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABFRIBiofrontera1.6123 of 5 stars3.53.00.00.00.60.01.3GRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial PharmaceuticalsN/AN/AN/AN/AAKTXAkari TherapeuticsN/AN/AN/AN/ABFRIBiofrontera3.00Buy$18.00818.37% UpsideGRTXGalera Therapeutics1.75ReduceN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$2.46 per shareN/AAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/ABFRIBiofrontera$34.07M0.29N/AN/A$3.16 per share0.62GRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$5.12M-$5.72N/AN/AN/AN/A-250.52%-183.24%5/10/2024 (Estimated)AKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A5/6/2024 (Estimated)BFRIBiofrontera-$20.13M-$15.82N/AN/AN/A-59.09%-344.98%-72.85%5/10/2024 (Estimated)GRTXGalera Therapeutics-$59.08M-$1.41N/A∞N/AN/AN/A-137.47%5/9/2024 (Estimated)Latest AKTX, BFRI, GRTX, and ADIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023GRTXGalera TherapeuticsN/A-$0.10-$0.10-$0.10N/AN/A3/15/2024Q4 2023BFRIBiofronteraN/A-$2.33-$2.33-$6.31N/A$10.60 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/AAKTXAkari TherapeuticsN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A4.904.90AKTXAkari TherapeuticsN/A0.950.95BFRIBiofronteraN/A1.280.67GRTXGalera TherapeuticsN/A4.364.36OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%AKTXAkari Therapeutics5.06%BFRIBiofrontera10.08%GRTXGalera Therapeutics50.77%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals14.47%AKTXAkari Therapeutics61.80%BFRIBiofrontera0.69%GRTXGalera Therapeutics6.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals44.05 million3.47 millionNo DataAKTXAkari Therapeutics97.92 million3.03 millionNot OptionableBFRIBiofrontera835.09 million5.05 millionNo DataGRTXGalera Therapeutics754.39 million50.64 millionOptionableAKTX, BFRI, GRTX, and ADIL HeadlinesSourceHeadlineGalera Therapeutics Seeks Strategic Alternatives Amid Financial Setbacks and Regulatory Challengesmsn.com - April 1 at 5:26 AMGalera Therapeutics: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updatesfinanznachrichten.de - March 28 at 2:09 PMGalera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updatesglobenewswire.com - March 28 at 7:00 AMGRTX Apr 2024 0.500 callfinance.yahoo.com - March 16 at 9:07 AMGalera Therapeutics, Inc. (GRTX)nz.finance.yahoo.com - March 12 at 5:23 PMGalera Therapeutics, Inc.edition.cnn.com - February 27 at 7:25 AMGalera Therapeutics Inc (GRTX)investing.com - February 4 at 12:37 AMGalera Therapeutics Stock (NASDAQ:GRTX) Dividends: History, Yield and Datesbenzinga.com - February 4 at 12:37 AMGalera Therapeutics Insiders Lose Out As Stock Sinks To US$0.17finance.yahoo.com - January 21 at 2:16 PMLocal publicly traded stocks lag far behind national indices in 2023bizjournals.com - January 16 at 1:33 PMDow Tumbles Over 200 Points; US Trade Gap Narrows In Novembermsn.com - January 9 at 2:28 PMGalera Therapeutics (GRTX) Price Target Increased by 7.14% to 0.38msn.com - November 28 at 2:59 AMGalera Therapeutics: Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updatesfinanznachrichten.de - November 14 at 8:41 AMGalera Therapeutics: Q3 Earnings Insightsbenzinga.com - November 14 at 8:41 AMGalera Reports Third Quarter 2023 Financial Results and Recent Corporate Updatesfinance.yahoo.com - November 14 at 8:41 AMGalera Therapeutics's Earnings Outlookbenzinga.com - November 13 at 2:56 PMUnderstanding the Risks of Investing in Galera Therapeutics Inc (GRTX)knoxdaily.com - November 8 at 7:21 AMUS Stocks Fall; Pfizer Swings To Q3 Lossbenzinga.com - November 1 at 5:19 PMGalera Therapeutics Inc (GRTX) rating downgrades by Piper Sandlerknoxdaily.com - November 1 at 5:19 PMDow Gains 50 Points; Global Payments Posts Upbeat Earningsbenzinga.com - October 31 at 3:16 PMGalera Therapeutics warns of potential shutdown as it halts clinical trials and stock tanksbizjournals.com - October 31 at 3:16 PMWhy Is Cancer Focused Galera Therapeutics Stock Sinking Today?msn.com - October 31 at 3:16 PMGalera plunges after citing risks to business continuitymsn.com - October 31 at 3:16 PMGalera Therapeutics: Galera Announces Receipt of Type A Meeting Minutes and Strategic Updatefinanznachrichten.de - October 31 at 10:16 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdial PharmaceuticalsNASDAQ:ADILAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Akari TherapeuticsNASDAQ:AKTXAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.BiofronteraNASDAQ:BFRIBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Galera TherapeuticsNASDAQ:GRTXGalera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.